Liquid biopsy diagnosis platform Freenome has raised $ 100 m in a series A funding round led by the venture capital firm Andreessen Partners . The 25-person company has said that its tests outperform current screening options for breast , prostate , colorectal and lung cancer . The firm 's technology uses a patient 's DNA to diagnose cancer , rather than relying on traditional tissue biopsies . However , no liquid biopsy firm has yet been able to pinpoint where a tumour is located or what the prognosis is . it’s into the doctor’s office, as long as it can get there first. It plans to use its funding to fund clinical trials with the help of 25 research partners .
Liquid biopsy diagnosis platform Freenome has raised $ 100 m in a series A funding round led by the venture capital firm Andreessen Partners . The 25-person company has said that its tests outperform current screening options for breast , prostate , colorectal and lung cancer . The firm 's technology uses a patient 's DNA to diagnose cancer , rather than relying on traditional tissue biopsies . However , no liquid biopsy firm has yet been able to pinpoint where a tumour is located or what the prognosis is . It plans to use its funding to fund clinical trials with the help of 25 research partners .